Day One Biopharmaceuticals Announces Financial Results Call
Day One Biopharmaceuticals (NASDAQ: DAWN) is making new strides in the biopharmaceutical sector, focusing on therapies that target significant health challenges affecting individuals of all ages. The company has scheduled a live conference call for stakeholders, during which they will release their financial results for both the fourth quarter and the entire year of 2024.
Conference Call Details
The event is set for an upcoming date and will commence at 4:30 p.m. ET. This call not only serves as a platform for Day One to present its financial performance, but also allows the company to discuss its advancements and ongoing projects in the biopharmaceutical field. Interested parties will find the audio of this pivotal event accessible through the Company’s official site.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals has positioned itself as a crucial player in the development of medicines designed to treat both child and adult diseases. It was established to combat the extensive delays that commonly accompany traditional drug development, especially for pediatric oncology therapies. This mission is rooted in the urgency to provide solutions that can be life-saving.
Innovation at Day One
What sets Day One apart is its dedication to identifying and nurturing groundbreaking therapeutics intended to enhance the life experiences of patients battling severe illnesses—as emphasized in their motto, progressing from Day One. Their innovative approach, referred to as "search & development," underscores the company's commitment to discover, acquire, and manage promising drug candidates that offer hope to patients and families alike.
Pioneering Pipeline Offerings
Among the company’s leading drug candidates is tovorafenib, marketed as OJEMDA™, along with DAY301 and a VRK1 inhibitor program. Each of these candidates stands as a testament to Day One's commitment to creating leading-edge treatments aimed at altering the landscape of medicines available for critical health conditions.
Company Presence and Contact
With its headquarters in Brisbane, the company fosters an environment that encourages innovation and progress. Additionally, individuals seeking more information on Day One can explore their website for comprehensive resources, including their pipeline of products and updates on investor relations.
For media inquiries, Laura Cooper, the Head of Communications, can be reached via email. For investor-related questions, PJ Kelleher from LifeSci Advisors is also available. These channels ensure that stakeholders receive timely information on the company’s developments.
Frequently Asked Questions
What is Day One Biopharmaceuticals known for?
Day One Biopharmaceuticals specializes in developing targeted therapies for life-threatening diseases in both children and adults.
When will the financial results be announced?
The financial results for Q4 and full-year 2024 will be announced during a scheduled conference call.
How can investors access the conference call?
Investors can listen to the live audio of the conference call via the company's official Investors & Media page.
What types of products does Day One offer?
Day One's product pipeline includes innovative medicines such as tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program.
How does Day One communicate with its stakeholders?
Day One utilizes its Investor Relations website and social media platforms for effective communication regarding news, announcements, and financial performance.
